Ruo Yu Chen
Plus aucun poste en cours
Fortune : - $ au 31/05/2024
Profil
Ruo Yu Chen is currently the Executive Director at Continent Pharmaceutical Inc. and Beijing Continent Pharmaceutical Co., Ltd.
She is also the Supervisor at GNI-EPS Pharmaceuticals, inc., Finance Controller at Cullgen, Inc., and Supervisor at Cullgen Shanghai, Inc. In addition, she holds the position of Chief Financial Officer at Gyre Therapeutics, Inc. starting in 2023 and Senior Vice President-Finance at GNI USA, Inc. starting in 2021.
Previously, she worked as the Director-Finance & Accounting at GNI Group Ltd.
from 2014 to 2021 and as the Manager-Internal Audit Division at Protiviti LLC.
Ms. Chen completed her undergraduate degree at Nankai University in 1992 and her graduate degree at the Graduate School of Economics Kyoto University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
-.--% | 19/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Ruo Yu Chen
| Sociétés | Poste | Début |
|---|---|---|
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 18/07/2018 |
GNI USA, Inc.
 GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA. | Corporate Officer/Principal | 01/01/2021 |
Cullgen, Inc.
 Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | - |
| Cullgen Shanghai, Inc. | Directeur/Membre du Conseil | - |
| GNI-EPS Pharmaceuticals, inc. | Directeur/Membre du Conseil | - |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/01/2018 |
Anciens postes connus de Ruo Yu Chen
| Sociétés | Poste | Fin |
|---|---|---|
| GNI GROUP LTD. | Comptroller/Controller/Auditor | 01/01/2021 |
Protiviti LLC
 Protiviti LLC Miscellaneous Commercial ServicesCommercial Services Part of Robert Half, Inc., Protiviti LLC is a business consulting firm that provides IT consulting, risk and compliance, digital transformation, and internal audit services. The company is based in Tokyo, Japan. Protiviti also offers a platform for alumni to connect, reminisce, and stay in touch, as well as to introduce, employ, and mentor fellow alumni. | Comptroller/Controller/Auditor | - |
Formation de Ruo Yu Chen
| Nankai University | Undergraduate Degree |
| Graduate School of Economics Kyoto University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GNI GROUP LTD. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
Protiviti LLC
Protiviti LLC Miscellaneous Commercial ServicesCommercial Services Part of Robert Half, Inc., Protiviti LLC is a business consulting firm that provides IT consulting, risk and compliance, digital transformation, and internal audit services. The company is based in Tokyo, Japan. Protiviti also offers a platform for alumni to connect, reminisce, and stay in touch, as well as to introduce, employ, and mentor fellow alumni. | Commercial Services |
GNI USA, Inc.
GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA. | Health Technology |
Cullgen, Inc.
Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | Health Technology |
| Cullgen Shanghai, Inc. | |
| GNI-EPS Pharmaceuticals, inc. | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
